At 08:50 am, Nifty futures on the Singapore Exchange (SGX) were trading 86 points or 0.87 per cent lower at 9,856, indicating a negative start for the domestic market on Monday
Here's a look at the top stocks that may remain in focus today -
RIL: Reliance Industries (RIL) partly-paid shares will make their stock market debut on Monday. These shares were issued in rights issue programme, which concluded on June 3 and garnered 1.6 times subscription. Besides, the company announced during the weekend the sale of 0.93 per cent equity stake in Jio Platforms to global alternative asset firm TPG on a fully diluted basis for Rs 4,546.8 crore. That apart, consumer-focused private equity firm L Catterton will an investment of Rs 1,894.50 crore in Jio Platforms at an equity value of Rs 4.91 trillion and an enterprise value of Rs 5.16 trillion.
Cadila: After Cipla, Jubilant Lifesciences and Hetero Labs, Gilead Sciences Inc. has now signed a non-exclusive licensing agreement with Cadila Healthcare Ltd (Zydus Cadila) for manufacturing and distribution of its investigational drug Remdesivir for treating Covid-19.
Dr Reddy's: Dr Reddy's Laboratories today announced that it has entered into a non-exclusive licensing agreement with Gilead Sciences, Inc. that will grant the Indian drug maker the right to register, manufacture and sell Gilead's investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.
Eicher Motors: Eicher Motors Ltd has posted a 45.5 per cent decline in profit before tax, at Rs 446.84 crore during the quarter ended March 31, 2020, from Rs 819.59 crore during same period last year. This is after its share of the loss of its Joint Venture VE Commercial Vehicle Ltd, which was a loss of Rs 14.01 crore. The JV had made a a profit of Rs 75.47 crore in the year-ago quarter.
BHEL: State-run engineering firm BHEL on Saturday reported a consolidated net loss of Rs 1,532.18 crore for the March quarter, mainly due to lower revenues and deferred tax.
PNB Housing Finance posted a pre-tax loss of Rs 351.18 crore on a standalone basis in the March quarter on a multi-fold rise in provisions for impairment on financial instruments and write-offs. The firm had posted a pre-tax profit of Rs 547.05 crore in the quarter ended March 2019 (Q4FY19), according to BSE filings. It booked a net loss of Rs 263.12 crore in Q4 against a net profit of Rs 371.12 crore in the same period previous year.